2 days ago
- Business
- Time Business News
New Advances in IAHA Injections for Orthopedic Care
Orthopedic intra-articular hyaluronic acid (IAHA) injection is a treatment where a natural substance found in hyaluronic acid-format fluid is injected into a joint, most commonly to relieve pain, pain, pain and improve mobility in patients with chronic osteoarthritis. The future of orthopedic intra-articular hyaluronic acid (IAHA) injection market looks promising the future, cases of increasing osteoarthritis, the patient's priority for non-surreal treatment, and is inspired by innovations in long-lasting ha formulations. Extending access to emerging markets such as outpatient settings, favorable regulatory support, and Asia-Pacific will further boost demand for increase in demand. Advances such as combination therapy and better distribution methods are also expected to increase the results of treatment and make market access wider.
Key Growth Drivers and Opportunities
Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals.
Challenges
The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent.
Innovation and Expansion
JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku
In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks.
Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks.
Inventive Sparks, Expanding Markets
Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
